Drug Trial Radar · NCT05459571
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Aug 9, 2022
Primary completion
Nov 24, 2025
Study completion Nov 24, 2025
Sponsor
- Lead sponsor
- Kite, A Gilead CompanyGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jul 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study was to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
Conditions
- Relapsed or Refractory Large B-cell Lymphoma
Interventions
Axicabtagene CiloleucelBiological
Administered intravenously
CyclophosphamideDrug
Administered intravenously
FludarabineDrug
Administered intravenously
DexamethasoneDrug
Administered orally or intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-emergent Cytokine Release Syndrome (CRS) as Per SeverityTime frame: Up to 2.2 years
- Percentage of Participants With Treatment-emergent Neurologic Events as Per SeverityTime frame: Up to 2.2 years
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California
UCLA
Los Angeles, California
Colorado Blood Cancer Institute
Denver, Colorado
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Oncology Hematology Care Clinical Trials, LLC
Cincinnati, Ohio
Prisma Health - Upstate
Greenville, South Carolina
Tennessee Oncology, PLLC
Nashville, Tennessee
Henry-Joyce Cancer Clinic
Nashville, Tennessee
Methodist Healthcare System of San Antonio
San Antonio, Texas
Intermountain Healthcare
Murray, Utah
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah
University of Virginia Health System
Charlottesville, Virginia
Virginia Oncology Associates
Norfolk, Virginia
Virginia Commonwealth University
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.